請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78306完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王繼娟(Chi-Chuan Wang) | |
| dc.contributor.author | Yu-Chen Chang | en |
| dc.contributor.author | 張祐禎 | zh_TW |
| dc.date.accessioned | 2021-07-11T14:50:23Z | - |
| dc.date.available | 2025-08-10 | |
| dc.date.copyright | 2020-09-10 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-07 | |
| dc.identifier.citation | 1. January, C.T., et al., 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, 2014. 64(21): p. 2246-2280. 2. Pasquini, M., et al., Variation in restarting antithrombotic drugs at hospital discharge after intracerebral hemorrhage. Stroke, 2014. 45(9): p. 2643-8. 3. Hart, R.G., L.A. Pearce, and M.I. Aguilar, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007. 146(12): p. 857-67. 4. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet, 2019. 393(10191): p. 2613-2623. 5. Nielsen, P.B., et al., Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. Circulation, 2015. 132(6): p. 517-525. 6. Hemphill, J.C., et al., Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke, 2015. 46(7): p. 2032-2060. 7. Go, A.S., et al., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama, 2001. 285(18): p. 2370-5. 8. Miyasaka, Y., et al., Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 2006. 114(2): p. 119-25. 9. Lee, C.H., et al., Characteristics of hospitalized patients with atrial fibrillation in Taiwan: a nationwide observation. Am J Med, 2007. 120(9): p. 819.e1-7. 10. Bhatt, H.V. and G.W. Fischer, Atrial Fibrillation: Pathophysiology and Therapeutic Options. J Cardiothorac Vasc Anesth, 2015. 29(5): p. 1333-40. 11. Iwasaki, Y.K., et al., Atrial fibrillation pathophysiology: implications for management. Circulation, 2011. 124(20): p. 2264-74. 12. Markides, V. and R.J. Schilling, Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart, 2003. 89(8): p. 939-43. 13. January, C.T., et al., 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation, 2014. 130(23): p. 2071-104. 14. Wolf, P.A., R.D. Abbott, and W.B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991. 22(8): p. 983-8. 15. Lin, H.J., et al., Stroke severity in atrial fibrillation. The Framingham Study. Stroke, 1996. 27(10): p. 1760-4. 16. Go, A.S., et al., Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation, 2014. 129(3): p. e28-e292. 17. Stewart, S., et al., A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med, 2002. 113(5): p. 359-64. 18. Krahn, A.D., et al., The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med, 1995. 98(5): p. 476-84. 19. Lip, G.Y., et al., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 2010. 137(2): p. 263-72. 20. Kirchhof, P., et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016. 37(38): p. 2893-2962. 21. Laupacis, A., et al., Antithrombotic therapy in atrial fibrillation. Chest, 1995. 108(4 Suppl): p. 352s-359s. 22. Connolly, S.J., et al., Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2009. 361(12): p. 1139-1151. 23. Giugliano, R.P., et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013. 369(22): p. 2093-2104. 24. Granger, C.B., et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011. 365(11): p. 981-992. 25. Patel, M.R., et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 2011. 365(10): p. 883-891. 26. Zhu, J., et al., Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. Pharmacotherapy, 2018. 38(9): p. 907-920. 27. Maura, G., et al., Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. BMJ open, 2019. 9(4): p. e026645-e026645. 28. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2009. 360(20): p. 2066-2078. 29. Connolly, S.J., et al., Apixaban in patients with atrial fibrillation. N Engl J Med, 2011. 364(9): p. 806-17. 30. van Asch, C.J., et al., Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol, 2010. 9(2): p. 167-76. 31. Poon, M.T., S.M. Bell, and R. Al-Shahi Salman, Epidemiology of Intracerebral Haemorrhage. Front Neurol Neurosci, 2015. 37: p. 1-12. 32. An, S.J., T.J. Kim, and B.-W. Yoon, Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. Journal of stroke, 2017. 19(1): p. 3-10. 33. Bejot, Y., et al., Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain, 2013. 136(Pt 2): p. 658-64. 34. Feigin, V.L., et al., Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol, 2009. 8(4): p. 355-69. 35. Tsai, C.F., B. Thomas, and C.L. Sudlow, Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology, 2013. 81(3): p. 264-72. 36. Hsieh, F.I., et al., Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation, 2010. 122(11): p. 1116-23. 37. Chan, C.L., H.W. Ting, and H.T. Huang, The incidence, hospital expenditure, and, 30 day and 1 year mortality rates of spontaneous intracerebral hemorrhage in Taiwan. J Clin Neurosci, 2014. 21(1): p. 91-4. 38. Yeh, S.J., et al., Pathogenetical subtypes of recurrent intracerebral hemorrhage: designations by SMASH-U classification system. Stroke, 2014. 45(9): p. 2636-42. 39. Qureshi, A.I., et al., Spontaneous intracerebral hemorrhage. N Engl J Med, 2001. 344(19): p. 1450-60. 40. Caceres, J.A. and J.N. Goldstein, Intracranial hemorrhage. Emerg Med Clin North Am, 2012. 30(3): p. 771-94. 41. Brott, T., et al., Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke, 1997. 28(1): p. 1-5. 42. Aronowski, J. and X. Zhao, Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke, 2011. 42(6): p. 1781-6. 43. Matsukawa, H., et al., Factors associated with lobar vs. non-lobar intracerebral hemorrhage. Acta Neurol Scand, 2012. 126(2): p. 116-21. 44. Smith, E.E. and F. Eichler, Cerebral Amyloid Angiopathy and Lobar Intracerebral Hemorrhage. Archives of Neurology, 2006. 63(1): p. 148-151. 45. Flaherty, M.L., Anticoagulant-associated intracerebral hemorrhage. Semin Neurol, 2010. 30(5): p. 565-72. 46. Eikelboom, J. and G. Merli, Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. Am J Med, 2016. 129(11s): p. S33-s40. 47. Ariesen, M.J., et al., Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke, 2003. 34(8): p. 2060-5. 48. Biffi, A., et al., Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol, 2010. 68(6): p. 934-43. 49. Sarwar, N., et al., Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 2010. 375(9733): p. 2215-22. 50. Arima, H., et al., Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke, 2006. 37(6): p. 1497-502. 51. Vermeer, S.E., et al., Long-term prognosis after recovery from primary intracerebral hemorrhage. Neurology, 2002. 59(2): p. 205-9. 52. Hanger, H.C., et al., The risk of recurrent stroke after intracerebral haemorrhage. J Neurol Neurosurg Psychiatry, 2007. 78(8): p. 836-40. 53. Izumihara, A., M. Suzuki, and T. Ishihara, Recurrence and extension of lobar hemorrhage related to cerebral amyloid angiopathy: multivariate analysis of clinical risk factors. Surg Neurol, 2005. 64(2): p. 160-4; discussion 164. 54. Tzourio, C., et al., APOE genotype, ethnicity, and the risk of cerebral hemorrhage. Neurology, 2008. 70(16): p. 1322-8. 55. Biffi, A., et al., Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology, 2010. 75(8): p. 693-8. 56. Huhtakangas, J., et al., Predictors for recurrent primary intracerebral hemorrhage: a retrospective population-based study. Stroke, 2013. 44(3): p. 585-90. 57. Yung, D., et al., Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol, 2012. 28(1): p. 33-9. 58. Claassen, D.O., et al., Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol, 2008. 65(10): p. 1313-8. 59. Eckman, M.H., et al., Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke, 2003. 34(7): p. 1710-6. 60. Ottosen, T.P., et al., Use of Antithrombotic Therapy and Long-Term Clinical Outcome Among Patients Surviving Intracerebral Hemorrhage. Stroke, 2016. 47(7): p. 1837-1843. 61. Murthy, S.B., et al., Restarting Anticoagulant Therapy After Intracranial Hemorrhage. Stroke, 2017. 48(6): p. 1594-1600. 62. Pennlert, J., et al., Antithrombotic Treatment Following Intracerebral Hemorrhage in Patients With and Without Atrial Fibrillation. Stroke, 2015. 46(8): p. 2094-2099. 63. Lopes, R.D., et al., Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 2010. 159(3): p. 331-339. 64. Ruff, C.T., et al., Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48). American Heart Journal, 2010. 160(4): p. 635-641.e2. 65. Nielsen, P.B., et al., Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. Stroke, 2019. 50(4): p. 939-946. 66. Saji, N., et al., Intracranial Hemorrhage Caused by Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)- Multicenter Retrospective Cohort Study in Japan. Circ J, 2015. 79(5): p. 1018-23. 67. Institute, P.H.R., NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH. 2017, https://ClinicalTrials.gov/show/NCT02998905. 68. van Nieuwenhuizen, K.M., et al., Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials, 2015. 16: p. 393. 69. Majeed, A., et al., Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke, 2010. 41(12): p. 2860-6. 70. Park, Y.A., et al., Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. Heart Rhythm, 2016. 13(9): p. 1794-802. 71. Kato, Y., et al., Resumption of Direct Oral Anticoagulants in Patients with Acute Spontaneous Intracerebral Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2019. 28(10). 72. Li, Y.G. and G.Y.H. Lip, Anticoagulation Resumption After Intracerebral Hemorrhage. Curr Atheroscler Rep, 2018. 20(7): p. 32. 73. National health insurance administration, m.o.h.a.w., taiwan, R.O.C, National health insurance annual report 2018-2019. 2018, National health insurance administration, ministry of health and welfare, taiwan, R.O.C. 74. Fauchier, L., et al., How to define valvular atrial fibrillation? Arch Cardiovasc Dis, 2015. 108(10): p. 530-9. 75. Ten Have, T.R., et al., Intent-to-Treat vs. Non-Intent-to-Treat Analyses under Treatment Non-Adherence in Mental Health Randomized Trials. Psychiatric annals, 2008. 38(12): p. 772-783. 76. Pisters, R., et al., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010. 138(5): p. 1093-100. 77. AbuDagga, A., et al., Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res, 2014. 14: p. 310. 78. Lauffenburger, J.C., et al., Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol, 2015. 115(8): p. 1095-101. 79. Hung, L.C., et al., Validation of a novel claims-based stroke severity index in patients with intracerebral hemorrhage. J Epidemiol, 2017. 27(1): p. 24-29. 80. Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med, 2009. 28(25): p. 3083-107. 81. Austin, P.C. and E.A. Stuart, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in Medicine, 2015. 34(28): p. 3661-3679. 82. Noordzij, M., et al., When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant, 2013. 28(11): p. 2670-7. 83. Fine, J.P. and R.J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association, 1999. 94(446): p. 496-509. 84. Becattini, C., A. Sembolini, and M. Paciaroni, Resuming anticoagulant therapy after intracerebral bleeding. Vascul Pharmacol, 2016. 84: p. 15-24. 85. Cole, S.R. and M.A. Hernán, Constructing inverse probability weights for marginal structural models. Am J Epidemiol, 2008. 168(6): p. 656-64. 86. Chiang, C.E., et al., 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm, 2017. 33(4): p. 345-367. 87. Gómez-Outes, A., et al., Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis, 2013. 2013: p. 640723. 88. Lip, G.Y., et al., Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost, 2016. 116(5): p. 975-986. 89. Patel, P.A., et al., Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circ Cardiovasc Qual Outcomes, 2015. 8(4): p. 383-92. 90. Chen, C.H., et al., Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda. Int J Cardiol, 2015. 191: p. 244-53. 91. Noseworthy, P.A., et al., Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. CHEST, 2016. 150(6): p. 1302-1312. 92. Deitelzweig, S., et al., Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Curr Med Res Opin, 2018. 34(3): p. 487-498. 93. Tepper, P.G., et al., Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS One, 2018. 13(11): p. e0205989. 94. Chiang, C.-E., et al., 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. Journal of the Formosan Medical Association, 2016. 115(11): p. 893-952. 95. Ogawa, S., et al., Fact-finding survey of antithrombotic treatment for prevention of cerebral and systemic thromboembolism in patients with non-valvular atrial fibrillation in 9 countries of the Asia-Pacific region. Journal of Arrhythmia, 2012. 28(1): p. 41-55. 96. January, C.T., et al., 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation, 2019. 140(2): p. e125-e151. 97. Harter, K., M. Levine, and S.O. Henderson, Anticoagulation drug therapy: a review. The western journal of emergency medicine, 2015. 16(1): p. 11-17. 98. Chan, N.C. and J.I. Weitz, Antithrombotic Agents. Circulation Research, 2019. 124(3): p. 426-436. 99. Chao, T.F., et al., Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. Circulation, 2016. 133(16): p. 1540-7. 100. Shen, A.Y.-J., et al., Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. Journal of the American College of Cardiology, 2007. 50(4): p. 309-315. 101. Tsai, C.-T., et al., Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. JAMA Network Open, 2020. 3(6): p. e206424-e206424. 102. Lee, S.-R., et al., Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage. Stroke, 2020. 51(2): p. 416-423. 103. Jones, S.R., S. Carley, and M. Harrison, An introduction to power and sample size estimation. Emergency Medicine Journal, 2003. 20(5): p. 453. 104. Franklin, J.M. and S. Schneeweiss, When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? Clin Pharmacol Ther, 2017. 102(6): p. 924-933. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78306 | - |
| dc.description.abstract | 背景 雖然使在心房顫動的病人中會使用抗凝血劑來預防中風，但是在心房顫動且有顱內出血病史的病人中，是否該使用抗血栓藥物來預防中風，目前還沒有一個定論。因此本研究的目標是要探討在心房顫動且有顱內出血病史的病人中，現行台灣之治療方式以及使用抗血栓藥物的成效分析。 方法 本研究為一回朔觀察性研究，以「衛生福利部衛生福利資料科學中心」之全人口檔進行分析，並篩選出2011年至2017年中有心房顫動及顱內出血病史的病人。首先，會記錄發生顱內出血前後之抗血栓藥物使用情形和顱內出血後之使用抗血栓藥物時間點。再者，病人會依據顱內出血後第90天的藥物使用情形區分為：抗凝血藥物使用者、抗血小板藥物使用者以及無使用抗血栓藥物者。抗血栓藥物包含：warfarin, apixaban, dabigatran, edoxaban, rivaroxaban, aspirin, clopidogrel, ticagrelor和prasugrel。最後，病人會依據顱內出血後第一筆處方被區分為NOAC使用者以及Warfarin使用者。治療權重倒數機率方式校正抗血栓藥物使用者與非使用者的族群間差異，並利用Cox比例風險來評估兩個族群(OAC組vs No AT組, AP組 vs No AT組, NOAC組 vs warfarin組)中發生事件的風險。 結果 本研究共納入5007有心房顫動及顱內出血病史的病人。在發生顱內出血前，warfarin是最多被使用的(35.54%)，在發生顱內出血後，抗血小板藥物是最多被使用的(49.34%)，使用NOACs的比例從20.24%上升至25.75%，多於75%的病人在顱內出血後半年內開始使用抗血栓藥物。 第一部分研究中共納入283抗凝血藥物使用者、214抗血小板使用者以及1069無使用抗血栓藥物者。相較於無使用抗血栓藥物者，在治療意向分析法中，抗凝血藥物使用者有非顯著低的中風(HR: 0.583; 95%Cl:0.434-0.784)以及血栓事件風險(HR: 0.566;95%Cl:0.432-0.742)；並且在根據治療分析中，有顯著低的中風(HR: 0.612;95%Cl:0.422-0.888)以及血栓事件風險(HR:0.602;95%Cl:0.433-0.835)。抗凝血藥物使用者有顯著高的再發顱內出血(HR:2.260;95%Cl:1.399-3.653)以及無顯著差別的重大出血風險(HR:1.397:95%Cl: 0.987-1.979)；抗凝血藥物使用者治療意向分析法(HR: 0.943;95%Cl:0.828-1.074)和根據治療分析(HR: 0.851;95%Cl: 0.721-1.005)有非顯著低的全因死亡率。相較於無使用抗血栓藥物者，在治療意向分析法中，抗血小板藥物使用者有非顯著差別的中風(HR: 0.902;95%Cl:0.700-1.163)以及血栓事件風險(HR:0.993;95%Cl:0.792-1.245)；並且在根據治療分析中，有非顯著高的中風(HR:1.127;95%Cl:0.814-1.560)以及血栓事件風險(HR:1.113;95%Cl: 0.837-1.480)。抗血小板藥物使用者無顯著高的再發顱內出血(HR: 1.626;95%Cl: 0.985-2.683)以及重大出血風險(HR:1.102;95%Cl:0.769-1.580)；抗血小板藥物使用者治療意向分析法(HR:0.941;95%Cl:0.830-1.066)和根據治療分析(HR: 0.878; 95%Cl:0.747-1.033)有非顯著低的全因死亡率。 第二部分研究中共納入333 NOAC使用者以及205 warfarin使用者。相較於warfarin，在治療意向分析法中，NOACs有顯著低的中風(HR:0.605;95%Cl:0.377-0.971)以及血栓事件風險(HR:0.579;95%Cl:0.367-0.915)；並且在根據治療分析中，有非顯著低的中風(HR:0.923;95%Cl:0.502-1.697)以及血栓事件風險(HR:0.811; 95%Cl:0.459-1.435)。NOACs有顯著低的再發顱內出血(HR:0.332:95%Cl: 0.167-0.658)以及重大出血風險(HR:0.363:95%Cl:0.219-0.602)；NOACs在治療意向分析法(HR:0.662;95%Cl:0.518-0.846)和根據治療分析(HR:0.603;95%Cl:0.432-0.841)有非顯著低的全因死亡率。 結論 相較於無使用抗血栓藥物，抗凝血藥物比抗血小板藥物有較低的中風風險以及較高的出血風險，並且，抗凝血藥和抗血小板藥物在全因死亡率風險中均無顯著差別。在有心房顫動及顱內出血病史的病人中，NOACs是相較於Warfarin而言比較好的治療選擇。 | zh_TW |
| dc.description.abstract | Background Although anticoagulants are recommended in atrial fibrillation (AF) for stroke prevention, whether to start or resume antithrombotic therapy for AF patients surviving intracranial hemorrhage (ICH) remains debatable. The goal of our research was to document the treatment pattern and investigate the effectiveness and safety among antithrombotic (AT) therapy in AF patients with subsequent ICH in Taiwan. Methods A retrospective cohort study using the Full Population Data of the Health and Welfare Database was performed. AF patients with subsequent ICH from 2011 to 2017 were included. Firstly, the use of antithrombotic agents before and after the ICH, and time to initiation of antithrombotic agents after the ICH were documented. Secondly, Patients were divided into oral anticoagulant (OAC) user, antiplatelet (AP) agent users and AT agent non-users based on which they were prescribed with on the date after 90 days since the discharge date of the ICH. AT agents were defined as warfarin, apixaban, dabigatran, edoxaban, rivaroxaban, aspirin, clopidogrel, ticagrelor, and prasugrel. Thirdly, Patients were divided into NOACs users and warfarin users based on the first prescription after discharging from the ICH. IPTW was used to balance baseline characteristics. Cox proportional hazard ratios were used to evaluate the relationship between the therapeutic intervention (OAC users vs AT agent non-users, AP agent users vs AT agent non-users and NOACs users vs warfarin users) and outcomes of interests. Results 5007 AF patients with subsequent ICH were included in the study. Before ICH, warfarin therapy was the most used (35.54%). After ICH, antiplatelet therapy was most used (49.34%). The percentage of NOACs increased from 20.24% before the ICH event to 25.75% after the ICH event. More than 75% of the patients initiated AT agents within 6 months after discharging from the ICH. There were 283 OAC users, 214 AP agent users, and 1069 AT agent non-users. Compared to no AT therapy, OAC were significant lower in ischemic stroke (IS) (HR: 0.583;95%Cl:0.434-0.784), and thromboembolic event (TE) (HR:0.566;95%Cl:0.432-0.742) in intention-to-treat (ITT) analysis, and were significant lower in IS (HR:0.612; 95%Cl:0.422-0.888), and TE (HR:0.602;95%Cl:0.433-0.835). OAC were significant higher in recurrent ICH (HR:2.260;95%Cl:1.399-3.653. OAC were non-significant lower in all-cause mortality than AT agent non-users in ITT analysis (HR:0.943; 95%Cl:0.828-1.074) and AsT analysis (HR:0.851;95%Cl:0.721-1.005). AP agent were non-significant lower in IS (HR:0.902;95%Cl:0.700-1.163), and non-significant difference in TE (HR:0.993;95%Cl:0.792-1.245) in ITT analysis, and were non-significant higher in IS (HR:1.127;95%Cl:0.814-1.560), and TE (HR:1.113;95%Cl: 0.837-1.480) in AsT analysis. AP agent were non-significant higher in recurrent ICH (HR:1.626;95%Cl:0.985-2.683), and non-significant higher in MB (HR:1.102;95%Cl: 0.769-1.580). AP agent were non-significant lower in all-cause mortality in ITT analysis (HR:0.941;95%Cl:0.830-1.066) and AsT analysis (HR: 0.878; 95%Cl:0.747-1.033). There were 333 NOAC users and 205 warfarin users. Compared to warfarin, NOACs were significant lower in IS(HR:0.605;95%Cl:0.377-0.971) and TE (HR:0.579;95%Cl: 0.367-0.915) in ITT analysis, and were non-significant lower in IS (HR:0.923;95%Cl: 0.502-1.697), and TE (HR:0.811; 95%Cl:0.459-1.435) in AsT analysis. NOACs were significant lower in recurrent ICH (HR:0.332:95%Cl: 0.167-0.658) and major bleeding (HR:0.363:95%Cl:0.219-0.602). NOACs were significant lower in all-cause mortality in ITT analysis (HR:0.662;95%Cl:0.518-0.846) and in AsT analysis (HR:0.603; 95%Cl:0.432-0.841). Conclusions Compared to no AT agent, OAC had lower risk in stroke and higher risk in bleeding than AP agent, also, OAC and AP agent had no difference in all-cause mortality. NOACs should be preferred over warfarin for AF patients with subsequent ICH. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T14:50:23Z (GMT). No. of bitstreams: 1 U0001-0608202018175200.pdf: 3397180 bytes, checksum: dfcdfdd3dc9a63a6331cb945e0648222 (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 致謝 i 摘要 ii ABSTRACT v TABLE OF CONTENTS viii LIST OF FIGURES x LIST OF TABLES xi CHAPTER 1: INTRODUCTION 1 CHAPTER 2: LITERATURE REVIEW 3 2.1 Atrial fibrillation 3 2.1.1 Epidemiology 3 2.1.2 Pathophysiology 3 2.1.3 Thromboembolic risk 4 2.1.4 Pharmacological prevention of stroke and systematic embolism 5 2.2 Intracerebral hemorrhage 6 2.2.1 Epidemiology 6 2.2.2 Pathophysiology 7 2.2.3 Risk factors 8 2.3 Recurrent intracerebral hemorrhage 8 2.3.1 Epidemiology 8 2.3.2 Risk factors 9 2.3.3 Antithrombotic drugs management after intracerebral hemorrhage 9 2.3.4 Anticoagulants management in atrial fibrillation 10 2.3.5 Optimal timing for reinitiating anticoagulants 11 2.4 Knowledge gap and study purpose 12 CHAPTER 3: METHOD 14 3.1 Data source 14 3.2 Study design 15 3.2.1 Study population 17 3.2.2 Exposure assessment 18 3.2.3 Follow-up duration 20 3.3 Outcome measures 20 3.4 Baseline characteristics and covariates 22 3.5 Statistical analysis 24 3.6 Sensitivity Analysis 25 CHAPTER 4: RESULTS 26 4.1 Treatment pattern 26 4.1.1 Study population 26 4.1.2 Antithrombotic agent prescription 26 4.1.3 Time to start/resumption of antithrombotic agent 27 4.2 Oral anticoagulant users versus antithrombotic agent non-users 29 4.2.1 Study population 29 4.2.2 Baseline characteristic 29 4.2.3 Outcomes 30 4.3 Antiplatelet agent users versus antithrombotic agent non-users 33 4.3.1 Study population 33 4.3.2 Baseline characteristic 34 4.3.3 Outcomes 36 4.4 NOAC users versus warfarin users 40 4.4.1 Study population 40 4.4.2 Baseline characteristic 41 4.4.3 Outcomes 43 4.5 Sensitivity analysis 47 CHAPTER 5: DISCUSSION 51 5.1 Treatment pattern (Aim 1) 51 5.2 Outcomes assessment (Aim 2) 53 5.2.1 Antithrombotic therapy vs No antithrombotic therapy 53 5.2.2 NOACs vs Warfarin 58 5.3 Strength and limitation 60 5.3.1 Strengths 60 5.3.2 Limitations 60 CHAPTER 6: CONCLUSION 61 CHAPTER 7: SUPPLEMENTARY METHOD 62 7.1 Method and study population 62 7.2 Results 64 7.2.1 Baseline characteristic 64 7.2.2 Outcomes 66 7.2.3 Discussion 67 FIGURES 70 TABLES 80 REFERENCE 105 | |
| dc.language.iso | zh-TW | |
| dc.subject | 顱內出血 | zh_TW |
| dc.subject | 抗凝血藥物 | zh_TW |
| dc.subject | 抗血小板藥物 | zh_TW |
| dc.subject | 抗血栓藥物 | zh_TW |
| dc.subject | 心房顫動 | zh_TW |
| dc.subject | Intracranial hemorrhage | en |
| dc.subject | Oral anticoagulant | en |
| dc.subject | Antiplatelet agent | en |
| dc.subject | Antithrombotic therapy | en |
| dc.subject | Atrial fibrillation | en |
| dc.title | 具有顱內出血病史之心房顫動病人的抗血栓藥物治療-回溯觀察性研究 | zh_TW |
| dc.title | Antithrombotic therapy in atrial fibrillation patients with intracranial hemorrhage | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林芳如(Fang-Ju Lin),林欣儀(Shin-Yi Lin),東雅惠(Yaa-Hui Dong),湯頌君(Sung-Chun Tang) | |
| dc.subject.keyword | 抗凝血藥物,抗血小板藥物,抗血栓藥物,心房顫動,顱內出血, | zh_TW |
| dc.subject.keyword | Oral anticoagulant,Antiplatelet agent,Antithrombotic therapy,Atrial fibrillation,Intracranial hemorrhage, | en |
| dc.relation.page | 110 | |
| dc.identifier.doi | 10.6342/NTU202002570 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2020-08-07 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
| dc.date.embargo-lift | 2025-08-10 | - |
| 顯示於系所單位： | 臨床藥學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0608202018175200.pdf 未授權公開取用 | 3.32 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。